EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Prediction of Clinical Trials Outcomes Based on Target Choice and Clinical Trial Design with Multi‐Modal Artificial Intelligence

Alex Aliper, Roman Kudrin iD, Daniil Polykovskiy, Petrina Kamya, Elena Tutubalina, Shan Chen, Feng Ren, Alex Zhavoronkov

Clinical Pharmacology & Therapeutics · 2023-11 · 114 (5) · 972-980

DOI: 10.1002/cpt.3008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 10.08.2023. Verfasst von Alex Aliper und 7 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine AI Ltd, Masdar City, Abu Dhabi, United Arab Emirates. Hauptthemen laut MEDLINE: Artificial Intelligence, Clinical Trials, Phase II as Topic, Research Design, Drug Discovery. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug discovery and development is a notoriously risky process with high failure rates at every stage, including disease modeling, target discovery, hit discovery, lead optimization, preclinical development, human safety, and efficacy studies. Accurate prediction of clinical trial outcomes may help significantly improve the efficiency of this process by prioritizing therapeutic programs that are more likely to succeed in clinical trials and ultimately benefit patients. Here, we describe inClinico, a transformer‐based artificial intelligence software platform designed to predict the outcome of phase II clinical trials. The platform combines an ensemble of clinical trial outcome prediction engines that leverage generative artificial intelligence and multimodal data, including omics, text, clinical trial design, and small molecule properties. inClinico was validated in retrospective, quasi‐prospective, and prospective validation studies internally and with pharmaceutical companies and financial institutions. The platform achieved 0.88 receiver operating characteristic area under the curve in predicting the phase II to phase III transition on a quasi‐prospective validation dataset. The first prospective predictions were made and placed on date‐stamped preprint servers in 2016. To validate our model in a real‐world setting, we published forecasted outcomes for several phase II clinical trials achieving 79% accuracy for the trials that have read out. We also present an investment application of inClinico using date stamped virtual trading portfolio demonstrating 35% 9‐month return on investment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceClinical Trials, Phase II as TopicResearch DesignDrug DiscoveryClinical Trials as TopicHumansSoftwareDrug Development

Autor:innen und Institutionen

  • Insilico Medicine AI Ltd, Masdar City, Abu Dhabi, United Arab Emirates.
  • Insilico Medicine Canada Inc., Quebec, Montreal, Canada.
  • Insilico Medicine Hong Kong Ltd, New Territories, Pak Shek Kok, Hong Kong.
  • Insilico Medicine Shanghai Ltd, Pudong New District, Shanghai, China.

ORCID-Profile: Roman Kudrin

Zitieren

APA

Aliper, A., Kudrin, R., Polykovskiy, D., Kamya, P., Tutubalina, E., Chen, S., Ren, F., & Zhavoronkov, A. (2023). Prediction of Clinical Trials Outcomes Based on Target Choice and Clinical Trial Design with Multi‐Modal Artificial Intelligence. Clinical Pharmacology & Therapeutics, 114(5), 972-980. https://doi.org/10.1002/cpt.3008

Vancouver

Aliper A, Kudrin R, Polykovskiy D, Kamya P, Tutubalina E, Chen S, et al. Prediction of Clinical Trials Outcomes Based on Target Choice and Clinical Trial Design with Multi‐Modal Artificial Intelligence. Clinical Pharmacology & Therapeutics. 2023;114(5):972-980. doi:10.1002/cpt.3008

BibTeX
@article{Aliper2023,
  author = {Aliper, Alex and Kudrin, Roman and Polykovskiy, Daniil and Kamya, Petrina and Tutubalina, Elena and Chen, Shan and Ren, Feng and Zhavoronkov, Alex},
  title = {Prediction of Clinical Trials Outcomes Based on Target Choice and Clinical Trial Design with Multi‐Modal Artificial Intelligence},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {114},
  number = {5},
  pages = {972--980},
  doi = {10.1002/cpt.3008}
}
Kostenlos starten →